表紙
市場調査レポート

甲状腺髄様癌:パイプライン製品の分析

Medullary Thyroid Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229769
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
甲状腺髄様癌:パイプライン製品の分析 Medullary Thyroid Cancer - Pipeline Review, H1 2016
出版日: 2016年03月16日 ページ情報: 英文 97 Pages
概要

甲状腺髄様癌は、甲状腺の傍濾胞細胞に由来する甲状腺がんの一形態です。傍濾胞細胞は、カルシトニンというホルモンを分泌しています。カルシトニンは、副甲状腺ホルモン (副甲状腺細胞で分泌されるタンパク質ホルモン) とともに働き、体内のカルシウム濃度を調節しています。甲状腺髄様癌の症状は、甲状腺がんの他の形態と類似しています。目に見えるしこり (結節) 、嚥下時の塊があるような感覚、嗄声、リンパ節腫大などの症状が見られます。治療は、化学療法、外科手術、生物学的療法、放射線療法などの選択肢があります。

当レポートでは、甲状腺髄様癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤プロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

甲状腺髄様癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Advenchen Laboratories, LLC
  • Ariad Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Immunomedics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AL-3818
  • CLM-29
  • everolimus
  • GI-6207
  • nintedanib
  • NMS-616
  • pasireotide
  • ponatinib hydrochloride
  • Pz-1
  • Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer
  • Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer
  • TF-2
  • vandetanib

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7748IDB

Summary

Global Markets Direct's, 'Medullary Thyroid Cancer - Pipeline Review, H1 2016', provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (Ro4and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
  • The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Medullary Thyroid Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Medullary Thyroid Cancer - Overview
    • Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis
  • Medullary Thyroid Cancer - Therapeutics under Development by Companies
  • Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
  • Medullary Thyroid Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Medullary Thyroid Cancer - Products under Development by Companies
  • Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes
  • Medullary Thyroid Cancer - Companies Involved in Therapeutics Development
    • Advenchen Laboratories, LLC
    • Ariad Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • Hutchison MediPharma Limited
    • Immunomedics, Inc.
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
  • Medullary Thyroid Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-3818 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLM-29 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLM-94 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GI-6207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NMS-616 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponatinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pz-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TF-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Medullary Thyroid Cancer - Recent Pipeline Updates
  • Medullary Thyroid Cancer - Dormant Projects
  • Medullary Thyroid Cancer - Discontinued Products
  • Medullary Thyroid Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013
      • Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Medullary Thyroid Cancer, H1 2016
  • Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Medullary Thyroid Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H1 2016
  • Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016
  • Medullary Thyroid Cancer - Pipeline by Novartis AG, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Medullary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Medullary Thyroid Cancer - Dormant Projects, H1 2016
  • Medullary Thyroid Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Medullary Thyroid Cancer, H1 2016
  • Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top